{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Yamamoto N"],"funding":["Swim Across America (SAA)","National Institutes of Health (NIH)","NCI NIH HHS","National Institutes of Health","Swim Across America"],"pagination":["733-745"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11967372"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["31(4)"],"pubmed_abstract":["<h4>Purpose</h4>The purpose of this study was to establish HMGA2 as a marker of basal-like disease in pancreatic ductal adenocarcinoma (PDAC) and explore its use as a biomarker for prognosis and treatment resistance.<h4>Experimental design</h4>We identified high-mobility group A2 (HMGA2) protein expression in basal PDAC cells in a single-cell RNA sequencing (RNA-seq) atlas of 172 patient samples. We then analyzed HMGA2 expression, along with expression of the classic marker GATA-binding factor 6 (GATA6), in a cohort of 580 PDAC samples with multiplex IHC. We further supplemented these data with an additional 30 diverse patient samples and multiple independent single-cell RNA-seq databases.<h4>Results</h4>We found that expression of HMGA2, but not previously described basal markers cytokera"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma."],"pmcid":["PMC11967372"],"funding_grant_id":["1R37CA241472","P20 CA252733","R01 CA223483","U01 CA284086","P30 CA015704","R01 CA248917","P50 CA285275","R01 CA161112","R01 CA286615","R37 CA241472","P50 CA272213"],"pubmed_authors":["Walsh T","Safyan RA","Jang GH","Yamamoto N","Kugel S","Bolton NM","Dobersch S","Haraguchi M","Samraj AN","Hingorani SR","Vij KR","DeNardo DG","Li L","Notta F","Mudd JL","Fields RC","Kang LI","Crawford HC","Steele NG","Ruzinova MB","Chiorean EG","Loveless I"],"additional_accession":[]},"is_claimable":false,"name":"HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma.","description":"<h4>Purpose</h4>The purpose of this study was to establish HMGA2 as a marker of basal-like disease in pancreatic ductal adenocarcinoma (PDAC) and explore its use as a biomarker for prognosis and treatment resistance.<h4>Experimental design</h4>We identified high-mobility group A2 (HMGA2) protein expression in basal PDAC cells in a single-cell RNA sequencing (RNA-seq) atlas of 172 patient samples. We then analyzed HMGA2 expression, along with expression of the classic marker GATA-binding factor 6 (GATA6), in a cohort of 580 PDAC samples with multiplex IHC. We further supplemented these data with an additional 30 diverse patient samples and multiple independent single-cell RNA-seq databases.<h4>Results</h4>We found that expression of HMGA2, but not previously described basal markers cytokera","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Feb","modification":"2026-05-29T17:23:05.691Z","creation":"2026-04-08T05:36:28.615Z"},"accession":"S-EPMC11967372","cross_references":{"pubmed":["39680021"],"doi":["10.1158/1078-0432.CCR-24-2200","10.1158/1078-0432.ccr-24-2200"]}}